BioSpace News Archive

Intelivation Technologies, a medical device company with a cutting-edge orthopedic and spine implant product portfolio announced that they have launched a new minimally invasive pedicle screw system.

Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic revenue growth in local currencies and increased operating profit with an EBIT margin of 18%. Combined SCIT and SLIT-drops sales exceeded expectations, while tablet sales were around DKK 35 million lower than planned on slower growth in new patient initiations. The full-year revenue and earnings outlook remains unchanged. Q1 2023 financial highlights Comparat

Theranexus and the Beyond Batten Disease Foundation, have announced receipt of approval from the Food and Drug Administration for the design and primary and secondary endpoints of the pivotal Phase III trial for Batten disease CLN3, at a meeting with the Division of Rare Diseases and Medical Genetics held in mid-April.

The first quarter of the year saw continued strong growth, record gross margin and the launching of our first IVDR-approved product.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2023, and provides a corporate update.

Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041.

BioNxt Solutions Inc. is pleased to announce that it has successfully completed a human pilot study for a leading European-based generic drug company.

Diagnostic company SphingoTec has been successfully re-certified according to ISO 13485 and received its first IVDR certificate for its IVD product sphingotest® penKid®.

Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a EUR 1.300.000 EFRO-OOST grant alongside Radboud university medical center and Pathologie-DNA to accelerate the development of AI technology for breast and skin cancer diagnostics.

The 2022 Annual report of Promore Pharma AB is now available on the Company’s website.